Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587439 · ClinicalTrials.gov registry record
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
A clinical trial of Lung Cancer and Genetic Disease, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 500
- Enrollment target
- 2
- Study locations
NCT05587439: Recruiting study of Lung Cancer and Genetic Disease, sponsored by Dana-Farber Cancer Institute.
NCT05587439 is a study of Lung Cancer and Genetic Disease that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 500 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05587439, a study of Lung Cancer and Genetic Disease, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to learn more about the inherited risk for developing lung cancer.
Primary Outcome
To determine the prevalence of rare germline EGFR T790M or other (e.g., EGFR V843I and R776H) mutations in lung cancer patients and in relatives of carriers of germline EGFR mutations
Conditions Studied
Interventions
- GENETIC Data and Specimen Collection
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-11-01 |
What NCT05587439 shows while recruiting
NCT05587439 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (47% lower).
The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Data and Specimen Collection is the first listed.
NCT05587439 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05587439 about?
NCT05587439 is a clinical study titled "Investigating Hereditary Risk In Thoracic Cancers (INHERIT)". The purpose of this research study is to learn more about the inherited risk for developing lung cancer.
What is the current status of trial NCT05587439?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-01-01. Estimated completion is 2027-11-01.
What conditions does trial NCT05587439 study?
This clinical trial studies the following conditions: Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases.
What interventions are being tested in trial NCT05587439?
The interventions under investigation include: Data and Specimen Collection (GENETIC).
Who is sponsoring clinical trial NCT05587439?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05587439 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05587439's enrollment target sits among peer trials
500 70th of 409 higher than 338 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI